pubs.acs.org/acsmedchemlett
REFERENCES
(15) Gold, L. H.; Balster, R. L. Evaluation of the cocaine-like
discriminative stimulus effects and reinforcing effects of
modafinil. Psychopharmacology 1996, 126, 286–292.
(16) Reichel, C. M.; See, R. E. Modafinil effects on reinstatement of
methamphetamine seeking in a rat model of relapse. Psy-
chopharmacology 2010, 210, 337–346.
(17) Jasinski, D. R. An evaluation of the abuse potential of
modafinil using methylphenidate as a reference. J. Psycho-
pharmacol. 2000, 14, 53–60.
(18) Vosburg, S. K.; Hart, C. L.; Haney, M.; Rubin, E.; Foltin, R. W.
Modafinil does not serve as a reinforcer in cocaine abusers.
Drug Alcohol Depend. 2010, 106, 233–236.
(19) Donovan, J. L.; Malcolm, R. J.; Markowitz, J. S.; DeVane, C. L.
Chiral analysis of d- and l-modafinil in human serum: Appli-
cation to human pharmacokinetic studies. Ther. Drug Monit.
2003, 25, 197–202.
(20) Dinges, D. F.; Arora, S.; Darwish, M.; Niebler, G. E. Pharmaco-
dynamic effects on alertness of single doses of armodafinil in
healthy subjects during a nocturnal period of acute sleep loss.
Curr. Med. Res. Opin. 2006, 22, 159–167.
(21) Robertson, P., Jr.; Hellriegel, E. T. Clinical pharmacokinetic
profile of modafinil. Clin. Pharmacokinet. 2003, 42, 123–137.
(22) Garnock-Jones, K. P.; Dhillon, S.; Scott, L. J. Armodafinil. CNS
Drugs 2009, 23, 793–803.
(23) Newman, A. H.; Allen, A. C.; Izenwasser, S.; Katz, J. L. Novel 3
alpha-(diphenylmethoxy)tropane analogs: Potent dopamine
uptake inhibitors without cocaine-like behavioral profiles.
J. Med. Chem. 1994, 37, 2258–2261.
(24) De Risi, C.; Ferraro, L.; Pollini, G. P.; Tanganelli, S.; Valente, F.;
Veronese, A. C. Efficient synthesis and biological evaluation
of two modafinil analogues. Bioorg. Med. Chem. 2008, 16,
9904–9910.
(25) Lafon, L. Benzylsulfinylacetamide derivatives and their ther-
apeutic use. European Patent 0097071A1, 1983.
(26) Prisinzano, T.; Podobinski, J.; Tidgewell, K.; Luo, M.; Swen-
son, D. Synthesis and determination of the absolute config-
uration of the enantiomers of modafinil. Tetrahedron: Asymmetry
2004, 15, 1053–1058.
(27) Zou, M. F.; Cao, J.; Kopajtic, T.; Desai, R. I.; Katz, J. L.; New-
man, A. H. Structure-activity relationship studies on a novel
series of (S)-2β-substituted 3alpha-[bis(4-fluoro- or 4-chloro-
phenyl)methoxy]tropane analogues for in vivo investigation.
J. Med. Chem. 2006, 49, 6391–6399.
(28) Kulkarni, S. S.; Grundt, P.; Kopajtic, T.; Katz, J. L.; Newman,
A. H. Structure-activity relationships at monoamine trans-
porters for a series of N-substituted 3alpha-(bis[4-fluorophe-
nyl]methoxy)tropanes: Comparative molecular field analysis,
synthesis, and pharmacological evaluation. J. Med. Chem.
2004, 47, 3388–3398.
(29) Newman, A. H.; Kline, R. H.; Allen, A. C.; Izenwasser, S.;
George, C.; Katz, J. L. Novel 40-substituted and 40,400-disubsti-
tuted 3 R-(diphenylmethoxy)tropane analogs as potent and
selective dopamine uptake inhibitors. J. Med. Chem. 1995, 38,
3933–3940.
(30) Katz, J. L.; Izenwasser, S.; Kline, R. H.; Allen, A. C.; Newman,
A. H. Novel 3R-diphenyl-methoxy-tropane analogs: Selective
dopamine uptake inhibitors with behavioral effects distinct
from those of cocaine. J. Pharmacol. Exp. Ther. 1999, 288,
302–315.
(1)
(2)
(3)
Ballon, J. S.; Feifel, D. A systematic review of modafinil:
Potential clinical uses and mechanisms of action. J. Clin.
Psychiatry 2006, 67, 554–566.
Minzenberg, M. J.; Carter, C. S. Modafinil: A review of
neurochemical actions and effects on cognition. Neuropsy-
chopharmacology 2008, 33, 1477–1502.
Dackis, C. A.; Kampman, K. M.; Lynch, K. G.; Pettinati, H. M.;
O'Brien, C. P. A double-blind, placebo-controlled trial of
modafinil for cocaine dependence. Neuropsychopharmacol-
ogy 2005, 30, 205–211.
(4)
(5)
Martinez-Raga, J.; Knecht, C.; Cepeda, S. Modafinil: a useful
medication for cocaine addiction? Review of the evidence
from neuropharmacological, experimental and clinical stud-
ies. Curr. Drug Abuse Rev. 2008, 1, 213–221.
Shearer, J.; Darke, S.; Rodgers, C.; Slade, T.; van Beek, I.;
Lewis, J.; Brady, D.; McKetin, R.; Mattick, R. P.; Wodak, A. A
double-blind, placebo-controlled trial of modafinil (200 mg/
day) for methamphetamine dependence. Addiction 2009,
104, 224–233.
(6)
(7)
Turner, D. C.; Robbins, T. W.; Clark, L.; Aron, A. R.; Dowson, J.;
Sahakian, B. J. Cognitive enhancing effects of modafinil in
healthy volunteers. Psychopharmacology 2003, 165, 260–269.
Rasetti, R.; Mattay, V. S.; Stankevich, B.; Skjei, K.; Blasi, G.;
Sambataro, F.; Arrillaga-Romany, I. C.; Goldberg, T. E.; Calli-
cott, J. H.; Apud, J. A.; Weinberger, D. R. Modulatory Effects of
Modafinil on Neural Circuits Regulating Emotion and Cogni-
tion. Neuropsychopharmacology 2010, 35, 2101–2109.
Ferraro, L.; Antonelli, T.; Tanganelli, S.; O'Connor, W. T.; Perez
de la Mora, M.; Mendez-Franco, J.; Rambert, F. A.; Fuxe, K.
The vigilance promoting drug modafinil increases extra-
cellular glutamate levels in the medial preoptic area and the
posterior hypothalamus of the conscious rat: prevention by
local GABAA receptor blockade. Neuropsychopharmacology
1999, 20, 346–356.
(8)
(9)
Madras, B. K.; Xie, Z.; Lin, Z.; Jassen, A.; Panas, H.; Lynch, L.;
Johnson, R.; Livni, E.; Spencer, T. J.; Bonab, A. A.; Miller, G. M.;
Fischman, A. J. Modafinil occupies dopamine and norepi-
nephrine transporters in vivo and modulates the transporters
and trace amine activity in vitro. J. Pharmacol. Exp. Ther.
2006, 319, 561–569.
(10) Mignot, E.; Nishino, S.; Guilleminault, C.; Dement, W. C.
Modafinil binds to the dopamine uptake carrier site with
low affinity. Sleep 1994, 17, 436–437.
(11) Zolkowska, D.; Jain, R.; Rothman, R. B.; Partilla, J. S.; Roth,
B. L.; Setola, V.; Prisinzano, T. E.; Baumann, M. H. Evidence
for the involvement of dopamine transporters in behavioral
stimulant effects of modafinil. J. Pharmacol. Exp. Ther. 2009,
329, 738–746.
(12) Volkow, N. D.; Fowler, J. S.; Logan, J.; Alexoff, D.; Zhu, W.;
Telang, F.; Wang, G. J.; Jayne, M.; Hooker, J. M.; Wong, C.;
Hubbard, B.; Carter, P.; Warner, D.; King, P.; Shea, C.; Xu, Y.;
Muench, L.; Apelskog-Torres, K. Effects of modafinil on
dopamine and dopamine transporters in the male human
brain: clinical implications. J. Am. Med. Assoc. 2009, 301,
1148–1154.
(13) Andersen, M. L.; Kessler, E.; Murnane, K. S.; McClung, J. C.;
Tufik, S.; Howell, L. L. Dopamine transporter-related effects
of modafinil in rhesus monkeys. Psychopharmacology 2010,
210, 439–448.
(14) Dopheide, M. M.; Morgan, R. E.; Rodvelt, K. R.; Schachtman,
T. R.; Miller, D. K. Modafinil evokes striatal [(3)H]dopamine
release and alters the subjective properties of stimulants. Eur.
J. Pharmacol. 2007, 568, 112–123.
r
2010 American Chemical Society
52
DOI: 10.1021/ml1002025 ACS Med. Chem. Lett. 2011, 2, 48–52
|